세계의 바이오센서 시장 예측(-2030년) : 컴포넌트별, 유형별, 제품별, 기술별, 용도별, 지역별

The global biosensors market is expected to reach USD 34.51 billion in 2025 from USD 54.37 billion by 2030, growing at a CAGR of 9.5% during this period. Market growth is driven by the rising number of infectious diseases in developing countries, increasing demand for rapid diagnosis and efficient monitoring solutions, and technological advancements such as miniaturization, nanotechnology, microfluidics, and new product innovations. Additionally, the growing demand in urban areas, where diagnostic devices are easily accessible and simple to use, is further boosting market growth. Governments worldwide are launching initiatives to improve diagnostics and drug services, aiming to ensure availability and access to diagnostic testing while reducing patients' out-of-pocket expenses.

"Embedded devices to account for the larger market share in 2030"

Embedded devices are commonly used in various applications such as point of care, home diagnostics, food and beverages, research labs, environmental monitoring, and biodefense. With the growth of the Internet of Things (IoT) devices, there has been a significant shift in connected healthcare applications. IoT enables real-time alerts, tracking, and monitoring, which allows for hands-on treatments, improved accuracy, timely interventions by doctors, and overall better patient care. Many healthcare facilities are beginning to adopt embedded solutions for medical devices with IoT capabilities to address the shortage of doctors in remote areas. These IoT-enabled medical devices help identify diseases and perform various tests to deliver accurate and reliable treatment to patients in remote locations. Consequently, the increasing use of embedded devices will boost the market growth of biosensors.

"Non-wearable (POC) biosensors to capture the largest share of the biosensors market throughout the forecast period"

The non-wearable biosensors market is a vibrant growth area driven by diverse applications, from handheld tools to lab systems and point-of-care diagnostics, vital in healthcare, environmental monitoring, and food safety. These biosensors, used in hospitals, research, food, and environmental sectors, enable real-time, on-site monitoring, helping address food quality challenges and meet safety standards. Market growth is fueled by increased awareness of environmental surveillance and the need for rapid devices for biodefense, food control, and pathogen detection.

"China to hold largest share in Asia Pacific of biosensors market in 2030"

The factors driving the biosensors market in China include rapid economic growth and an aging population, along with government efforts to improve healthcare services. Many multinational exporters and producers operating in China have adopted strategies such as acquisitions or strategic partnerships that support reliable domestic distribution and service infrastructure. In contrast, many domestic manufacturers, particularly those focused on export markets outside of China, lack strong distribution and service networks within the country. China is the most populous country in the world, and with the one-child policy, the elderly population is expected to increase in the future. As the population ages, there will likely be a significant rise in the incidence of various disorders, including heart diseases.

Extensive primary interviews were conducted with key industry experts in the biosensors market to determine and verify the market size for various segments and subsegments gathered through secondary research. The breakdown of primary participants for the report is shown below: The study includes insights from various industry experts, from component suppliers to Tier 1 companies and OEMs. The breakdown of the primary participants is as follows:

• By Company Type: Tier 1-40%, Tier 2-35%, and Tier 3-25%
• By Designation: C-level Executives-45%, Directors-35%, and Others-20%
• By Region: North America-30%, Europe-22%, Asia Pacific-40%, and RoW-8%

Abbott Laboratories (US), F. Hoffmann-La Roche Ltd (Switzerland), Medtronic (Ireland), Bio-Rad Laboratories, Inc. (US), DuPont (US), Biosensors International Group, Ltd. (Singapore), Dexcom, Inc. (US), Masimo (US), Nova Biomedical (US), Universal Biosensors (Australia), and ACON Laboratories (US) are some key players in the biosensors market.

The study includes an in-depth competitive analysis of these key players in the biosensors market, with their company profiles, recent developments, and key market strategies.

Study Coverage: This research report categorizes the biosensors market based on type (sensor patches, embedded devices), product (wearable, non-wearable), technology (electrochemical, optical, piezoelectric, thermal, nanomechanical), component (bioreceptor molecules, biological elements, transducers), application (POC, home diagnostics, research labs, environmental monitoring, food & beverages, biodefense), and region (North America, Europe, Asia Pacific and RoW). The report describes the major drivers, restraints, challenges, and opportunities pertaining to the biosensors market and forecasts the same till 2030. The report also consists of leadership mapping and analysis of all the companies included in the biosensor ecosystem.

Key Benefits of Buying the Report The report will help the market leaders/new entrants in this market by providing information on the closest approximations of the revenue numbers for the overall biosensors market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

• Analysis of key drivers (emergence of nanotechnology-based biosensors, technological advancements, increasing use of biosensors to monitor glucose levels in individuals with diabetes, government initiatives to support diagnostics) restraints (reluctance to adopt new treatment practices, high costs of R&D), opportunities (emerging markets in developing countries, food & environmental monitoring applications, growth opportunities in wearables) and challenges (regulatory barriers and long certification & approval cycles) influencing the growth of the biosensors market
• Product Development/Innovation: Detailed insights into upcoming technologies, research and development activities, and the latest product and service launches in the biosensors market
• Market Development: Comprehensive information about lucrative markets - the report analyzes the biosensors market across varied regions
• Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the biosensors market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players, such as Abbott Laboratories (US), F. Hoffmann-La Roche Ltd (Switzerland), Medtronic (Ireland), Bio-Rad Laboratories, Inc. (US), DuPont (US), Biosensors International Group, Ltd. (Singapore), Dexcom, Inc. (US), Masimo (US), Nova Biomedical (US), Universal Biosensors (Australia), and ACON Laboratories (US) in the biosensors market

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
  • 1.2.1 INCLUSIONS AND EXCLUSIONS
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS & REGIONS COVERED
  • 1.3.2 YEARS CONSIDERED
  • 1.3.3 CURRENCY CONSIDERED
  • 1.3.4 UNITS CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 List of major secondary sources
    • 2.1.1.2 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 List of primary interview participants
    • 2.1.2.2 Key data from primary sources
    • 2.1.2.3 Breakdown of primaries
    • 2.1.2.4 Key industry insights
  • 2.1.3 SECONDARY AND PRIMARY RESEARCH
• 2.2 MARKET SIZE ESTIMATION METHODOLOGY
  • 2.2.1 BOTTOM-UP APPROACH
  • 2.2.2 TOP-DOWN APPROACH
    • 2.2.2.1 Approach to derive market size (supply side)
• 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.4 RESEARCH ASSUMPTIONS
• 2.5 RESEARCH LIMITATIONS
• 2.6 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 ATTRACTIVE OPPORTUNITIES IN BIOSENSORS MARKET
• 4.2 BIOSENSORS MARKET FOR WEARABLE DEVICES, BY TYPE
• 4.3 BIOSENSORS MARKET IN NORTH AMERICA, BY COUNTRY AND BY PRODUCT
• 4.4 BIOSENSORS MARKET, BY COUNTRY

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Emergence of nanotechnology-based biosensors
    • 5.2.1.2 Technological advancements in recent years
    • 5.2.1.3 Increasing use of biosensors to monitor glucose levels in individuals with diabetes
    • 5.2.1.4 Supportive government initiatives for diagnostics
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Reluctance to adopt new treatment practices
    • 5.2.2.2 High cost of biosensor R&D
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Emerging markets in developing countries
    • 5.2.3.2 Rising food and environmental monitoring applications
    • 5.2.3.3 Growth opportunities in wearables
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Regulatory barriers and long certification & approval cycles
• 5.3 VALUE CHAIN ANALYSIS
• 5.4 ECOSYSTEM ANALYSIS
• 5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.6 PRICING ANALYSIS
  • 5.6.1 INDICATIVE SELLING PRICE TREND OF GLUCOSE MONITORING SYSTEMS, BY PRODUCT TYPE, 2025
  • 5.6.2 INDICATIVE SELLING PRICE OF GLUCOSE MONITORING SYSTEMS, BY COMPANY, 2025
  • 5.6.3 INDICATIVE SELLING PRICE TREND OF GLUCOSE MONITORING SYSTEMS, BY REGION
• 5.7 TECHNOLOGY ANALYSIS
  • 5.7.1 KEY TECHNOLOGIES
    • 5.7.1.1 Multiplexed Biosensors
  • 5.7.2 COMPLEMENTARY TECHNOLOGIES
    • 5.7.2.1 AI-Integrated Biosensing Platforms
  • 5.7.3 ADJACENT TECHNOLOGIES
    • 5.7.3.1 Drug Delivery Systems
• 5.8 CASE STUDY ANALYSIS
  • 5.8.1 CASE STUDY 1: I-STAT SYSTEM HELPS PATIENTS AT ROCHDALE URGENT CARE CENTER
  • 5.8.2 CASE STUDY 2: INTEGRATED HEALTH SOLUTION PROVIDED COST SAVINGS AND INCREASED EFFICIENCY
  • 5.8.3 CASE STUDY 3: IMPROVING MOBILITY FOR PATIENTS AND REDUCING FALSE ALARMS FOR STAFF AT SUB-ACUTE CHILDREN'S HOSPITAL
  • 5.8.4 CASE STUDY 4: ENABLING SEAMLESS DATA TRANSMISSION FROM PATIENT'S HOME
• 5.9 INVESTMENT AND FUNDING SCENARIO
• 5.10 IMPACT OF GEN AI/AI ON BIOSENSORS MARKET
• 5.11 PATENT ANALYSIS
• 5.12 TRADE ANALYSIS
• 5.13 PORTER'S FIVE FORCES ANALYSIS
  • 5.13.1 INTENSITY OF COMPETITIVE RIVALRY
  • 5.13.2 THREAT OF SUBSTITUTES
  • 5.13.3 BARGAINING POWER OF BUYERS
  • 5.13.4 BARGAINING POWER OF SUPPLIERS
  • 5.13.5 THREAT OF NEW ENTRANTS
• 5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.14.2 BUYING CRITERIA
• 5.15 KEY CONFERENCES AND EVENTS, 2025-2026
• 5.16 REGULATORY LANDSCAPE AND STANDARDS
  • 5.16.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.16.2 STANDARDS
• 5.17 IMPACT OF 2025 US TARIFFS-BIOSENSORS MARKET
  • 5.17.1 INTRODUCTION
  • 5.17.2 KEY TARIFF RATES
  • 5.17.3 PRICE IMPACT ANALYSIS
  • 5.17.4 IMPACT ON COUNTRIES/REGIONS
    • 5.17.4.1 US
    • 5.17.4.2 Europe
    • 5.17.4.3 Asia Pacific
  • 5.17.5 IMPACT ON APPLICATIONS
    • 5.17.5.1 Point of Care (PoC)
    • 5.17.5.2 Home Diagnostics

6 BIOSENSORS MARKET, BY COMPONENT

• 6.1 INTRODUCTION
• 6.2 BIORECEPTOR MOLECULES
  • 6.2.1 ANTIBODIES AND PROTEINS ARE ALSO USED AS BIORECEPTOR MOLECULES IN BIOSENSORS
• 6.3 BIOLOGICAL ELEMENTS
  • 6.3.1 BIOLOGICAL ELEMENTS ARE MATERIALS RELATED TO BIOMOLECULES
• 6.4 TRANSDUCERS
  • 6.4.1 TRANSDUCER CONVERTS BIOCHEMICAL ACTIVITIES INTO ELECTRICAL SIGNALS

7 BIOSENSORS MARKET, BY TYPE

• 7.1 INTRODUCTION
• 7.2 SENSOR PATCHES
  • 7.2.1 WIDE-RANGE MONITORING OF VITAL SIGNS AND OTHER REQUIRED PARAMETERS
• 7.3 EMBEDDED DEVICES
  • 7.3.1 BROAD-SPECTRUM DETECTION OF BIOLOGICAL ANALYTES, HIGH SUCCESS RATES IN MEDICAL LABS AND FOOD BIOANALYSES

8 BIOSENSORS MARKET, BY PRODUCT

• 8.1 INTRODUCTION
• 8.2 WEARABLE BIOSENSORS
  • 8.2.1 WRISTWEAR
    • 8.2.1.1 Real-time health and fitness tracking and monitoring
  • 8.2.2 EYEWEAR
    • 8.2.2.1 Smart glasses and smart lenses to have significant presence in market in coming years
  • 8.2.3 FOOTWEAR
    • 8.2.3.1 Help in monitoring kilometers run, calories burned, workout hours, blood pressure, and other fitness & health-related data
  • 8.2.4 NECKWEAR
    • 8.2.4.1 Trendy devices that can help monitor fitness and health
  • 8.2.5 BODYWEAR
    • 8.2.5.1 Have potential to equip clothes used for daily wear with smart capabilities, making detection of body movements possible
  • 8.2.6 OTHER WEARABLE BIOSENSORS
• 8.3 NON-WEARABLE (POC) BIOSENSORS
  • 8.3.1 REAL-TIME ON-SITE MONITORING OF PRODUCTION PROCESSES

9 BIOSENSORS MARKET, BY TECHNOLOGY

• 9.1 INTRODUCTION
• 9.2 ELECTROCHEMICAL BIOSENSORS
  • 9.2.1 AMPEROMETRIC SENSORS
    • 9.2.1.1 Blood glucose sensors
      • 9.2.1.1.1 Suitable for medical devices for monitoring blood glucose
  • 9.2.2 POTENTIOMETRIC SENSORS
    • 9.2.2.1 Immunosensors
      • 9.2.2.1.1 Label-free detection and quantification of immune complex
  • 9.2.3 CONDUCTOMETRIC SENSORS
    • 9.2.3.1 Studies in enzymatic reactions and practical applications such as drug and pollutant detection to propel market
• 9.3 OPTICAL BIOSENSORS
  • 9.3.1 SPR BIOSENSORS
    • 9.3.1.1 Measure interactions in real-time with high sensitivity and without needing labels
  • 9.3.2 COLORIMETRIC BIOSENSORS
    • 9.3.2.1 Used in various applications, such as detection and identification of virulence activities
  • 9.3.3 FLUORESCENCE BIOSENSORS
    • 9.3.3.1 Provide better sensitivities and specificities, as well as ease of labeling, while detection
• 9.4 PIEZOELECTRIC BIOSENSORS
  • 9.4.1 ACOUSTIC BIOSENSORS
    • 9.4.1.1 Monitor changes in physical properties of acoustic waves in response to measurand
  • 9.4.2 MICROCANTILEVER BIOSENSORS
    • 9.4.2.1 Promising tool for detecting biomolecular interactions with improved accuracy
• 9.5 THERMAL BIOSENSORS
  • 9.5.1 STABILITY, NO NEED FOR FREQUENT RECALIBRATION, AND INSENSITIVITY TO OPTICAL AND ELECTROCHEMICAL PROPERTIES SUPPORT ADOPTION
• 9.6 NANOMECHANICAL BIOSENSORS
  • 9.6.1 RAPID, SENSITIVE, AND SELECTIVE DETECTION OF BIOLOGICAL AND BIOCHEMICAL ENTITIES

10 BIOSENSORS MARKET, BY APPLICATION

• 10.1 INTRODUCTION
• 10.2 POC
  • 10.2.1 GLUCOSE MONITORING
    • 10.2.1.1 Rising prevalence of diabetes, advancements in self-monitoring, and growing awareness about PoC testing
  • 10.2.2 CARDIAC MARKER DETECTION
    • 10.2.2.1 Sedentary urban lifestyles driving prevalence of cardiovascular diseases
  • 10.2.3 INFECTIOUS DISEASE DETECTION
    • 10.2.3.1 Detection of toxins, bacteria, and viruses in physiological and environmental matrices
  • 10.2.4 COAGULATION MONITORING
    • 10.2.4.1 Growing use of anticoagulant therapy, coupled with adoption of self-testing kits for use at home
  • 10.2.5 PREGNANCY TESTING
    • 10.2.5.1 Growing preference of women for confidentiality and accessibility of test results
  • 10.2.6 BLOOD GAS & ELECTROLYTE DETECTION
    • 10.2.6.1 Growing global aging population to drive market
  • 10.2.7 TUMOR/CANCER MARKER DETECTION
    • 10.2.7.1 Increasing number of people suffering from cancer and growth in investments in cancer research
  • 10.2.8 URINALYSIS TESTING
    • 10.2.8.1 Rising number of urinary tract infections among individuals
  • 10.2.9 CHOLESTEROL TESTING
    • 10.2.9.1 Increasing prevalence of CVDs due to aging and obese population
• 10.3 HOME DIAGNOSTICS
  • 10.3.1 GLUCOSE MONITORING
    • 10.3.1.1 Growing preference for self-monitoring blood glucose devices
  • 10.3.2 PREGNANCY TESTING
    • 10.3.2.1 Need for portable and user-friendly pregnancy testing devices
  • 10.3.3 CHOLESTEROL TESTING
    • 10.3.3.1 Growth of diseases due to increased cholesterol levels in individuals
• 10.4 RESEARCH LABS
  • 10.4.1 NEED FOR BIOSENSOR-BASED PRODUCT DEVELOPMENT FOR EARLY MONITORING OF DISEASES
• 10.5 ENVIRONMENTAL MONITORING
  • 10.5.1 DETECTION OF CONTAMINANTS IN COMPLEX MATRICES WITH SEVERAL ADVANTAGES TO ENHANCE MARKET GROWTH
• 10.6 FOOD & BEVERAGES
  • 10.6.1 BIOSENSORS USED FOR PATHOGEN DETECTION TO HELP MEET STRINGENT FOOD STANDARDS
• 10.7 BIODEFENSE
  • 10.7.1 USE OF BIOSENSORS TO DETECT MICROBIAL PATHOGENS DURING BIOLOGICAL WARFARE

11 BIOSENSORS MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 US
    • 11.2.1.1 Availability of and interest in biosensor-based POC to drive market
  • 11.2.2 CANADA
    • 11.2.2.1 Increasing government support to propel market growth
  • 11.2.3 MEXICO
    • 11.2.3.1 Use of biosensors for detecting cardiovascular disorders to propel market growth in Mexico
• 11.3 EUROPE
  • 11.3.1 GERMANY
    • 11.3.1.1 Monitoring chronic diseases to escalate biosensors market growth
  • 11.3.2 FRANCE
    • 11.3.2.1 Technological advancements in healthcare systems to drive growth
  • 11.3.3 UK
    • 11.3.3.1 Rising cardiac diseases and aging population to drive market
  • 11.3.4 ITALY
    • 11.3.4.1 Growing private sector results in increasing demand for biosensors for various applications
  • 11.3.5 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 CHINA
    • 11.4.1.1 Government initiatives for enhancing healthcare products and services to propel market growth
  • 11.4.2 JAPAN
    • 11.4.2.1 Increase in standard of living, rising health awareness, and surge in aging population to support market growth
  • 11.4.3 INDIA
    • 11.4.3.1 Growing population in India to escalate demand for biosensors in healthcare
  • 11.4.4 REST OF ASIA PACIFIC
• 11.5 REST OF THE WORLD
  • 11.5.1 SOUTH AMERICA
    • 11.5.1.1 Growing environment-related concerns have boosted adoption of biosensors for environmental monitoring
  • 11.5.2 MIDDLE EAST
    • 11.5.2.1 Government and private support to drive adoption of POC testing kits will favor demand for biosensors
    • 11.5.2.2 GCC Countries
      • 11.5.2.2.1 Saudi Arabia
      • 11.5.2.2.2 UAE
      • 11.5.2.2.3 Rest of GCC Countries
    • 11.5.2.3 Rest of Middle East
  • 11.5.3 AFRICA
    • 11.5.3.1 Increasing penetration in consumer electronics and medical devices

12 COMPETITIVE LANDSCAPE

• 12.1 OVERVIEW
• 12.2 STRATEGIES ADOPTED BY KEY PLAYERS, 2021-2024
• 12.3 REVENUE ANALYSIS, 2022-2024
• 12.4 MARKET SHARE ANALYSIS, 2024
• 12.5 COMPANY VALUATION AND FINANCIAL METRICS
• 12.6 BRAND/PRODUCT COMPARISON
• 12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 12.7.1 STARS
  • 12.7.2 EMERGING LEADERS
  • 12.7.3 PERVASIVE PLAYERS
  • 12.7.4 PARTICIPANTS
  • 12.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 12.7.5.1 Company footprint
    • 12.7.5.2 Region footprint
    • 12.7.5.3 Product footprint
    • 12.7.5.4 Type footprint
    • 12.7.5.5 Technology footprint
    • 12.7.5.6 Application footprint
• 12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 12.8.1 PROGRESSIVE COMPANIES
  • 12.8.2 RESPONSIVE COMPANIES
  • 12.8.3 DYNAMIC COMPANIES
  • 12.8.4 STARTING BLOCKS
  • 12.8.5 COMPETITIVE BENCHMARKING OF STARTUPS/SMES
    • 12.8.5.1 Detailed list of key startups/SMEs
    • 12.8.5.2 Competitive benchmarking of key startups/SMEs
• 12.9 COMPETITIVE SCENARIO
  • 12.9.1 PRODUCT LAUNCHES, APPROVALS, AND ENHANCEMENTS
  • 12.9.2 DEALS
  • 12.9.3 EXPANSIONS

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
  • 13.1.1 ABBOTT LABORATORIES
    • 13.1.1.1 Business overview
    • 13.1.1.2 Products/Solutions/Services offered
    • 13.1.1.3 Recent developments
      • 13.1.1.3.1 Product enhancements
      • 13.1.1.3.2 Deals
    • 13.1.1.4 MnM view
      • 13.1.1.4.1 Key strengths/Right to win
      • 13.1.1.4.2 Strategic choices
      • 13.1.1.4.3 Weaknesses/Competitive threats
  • 13.1.2 F. HOFFMANN-LA ROCHE LTD
    • 13.1.2.1 Business overview
    • 13.1.2.2 Products/Solutions/Services offered
    • 13.1.2.3 Recent developments
      • 13.1.2.3.1 Deals
    • 13.1.2.4 MnM view
      • 13.1.2.4.1 Key strengths/Right to win
      • 13.1.2.4.2 Strategic choices
      • 13.1.2.4.3 Weaknesses/Competitive threats
  • 13.1.3 MEDTRONIC
    • 13.1.3.1 Business overview
    • 13.1.3.2 Products/Services/Solutions offered
    • 13.1.3.3 Recent developments
      • 13.1.3.3.1 Product approvals
      • 13.1.3.3.2 Deals
    • 13.1.3.4 MnM view
      • 13.1.3.4.1 Key strengths/Right to win
      • 13.1.3.4.2 Strategic choices
      • 13.1.3.4.3 Weaknesses/Competitive threats
  • 13.1.4 BIO-RAD LABORATORIES, INC.
    • 13.1.4.1 Business overview
    • 13.1.4.2 Products/Solutions/Services offered
    • 13.1.4.3 MnM view
      • 13.1.4.3.1 Key strengths/Right to win
      • 13.1.4.3.2 Strategic choices
      • 13.1.4.3.3 Weaknesses/Competitive threats
  • 13.1.5 DUPONT
    • 13.1.5.1 Business overview
    • 13.1.5.2 Products/Solutions/Services offered
    • 13.1.5.3 Recent developments
      • 13.1.5.3.1 Deals
      • 13.1.5.3.2 Expansion
    • 13.1.5.4 MnM view
      • 13.1.5.4.1 Key strengths/Right to win
      • 13.1.5.4.2 Strategic choices
      • 13.1.5.4.3 Weaknesses/Competitive threats
  • 13.1.6 BIOSENSORS INTERNATIONAL GROUP, LTD.
    • 13.1.6.1 Business overview
    • 13.1.6.2 Products/Solutions/Services offered
    • 13.1.6.3 Recent developments
      • 13.1.6.3.1 Product approvals
  • 13.1.7 CYTIVA
    • 13.1.7.1 Business overview
    • 13.1.7.2 Products/Solutions/Services offered
    • 13.1.7.3 Recent developments
      • 13.1.7.3.1 Deals
  • 13.1.8 DEXCOM, INC.
    • 13.1.8.1 Business overview
    • 13.1.8.2 Products/Solutions/Services offered
    • 13.1.8.3 Recent developments
      • 13.1.8.3.1 Product launches
  • 13.1.9 LIFESCAN IP HOLDINGS, LLC
    • 13.1.9.1 Business overview
    • 13.1.9.2 Products/Solutions/Services offered
  • 13.1.10 MASIMO
    • 13.1.10.1 Business overview
    • 13.1.10.2 Products/Solutions/Services offered
    • 13.1.10.3 Recent developments
      • 13.1.10.3.1 Deals
  • 13.1.11 NOVA BIOMEDICAL
    • 13.1.11.1 Business overview
    • 13.1.11.2 Products/Solutions/Services offered
    • 13.1.11.3 Recent developments
      • 13.1.11.3.1 Deals
  • 13.1.12 UNIVERSAL BIOSENSORS
    • 13.1.12.1 Business overview
    • 13.1.12.2 Products/Solutions/Services offered
• 13.2 OTHER PLAYERS
  • 13.2.1 ACON LABORATORIES
  • 13.2.2 CONDUCTIVE TECHNOLOGIES
  • 13.2.3 EASTPRINT INCORPORATED
  • 13.2.4 IST AG
  • 13.2.5 LIFESIGNALS
  • 13.2.6 NEUROSKY
  • 13.2.7 PINNACLE TECHNOLOGY
  • 13.2.8 SD BIOSENSOR, INC.
  • 13.2.9 VITALCONNECT
  • 13.2.10 XSENSIO
  • 13.2.11 ZIMMER AND PEACOCK
  • 13.2.12 PARAGRAF LIMITED
  • 13.2.13 DYNAMIC BIOSENSORS
  • 13.2.14 LINEXENS
  • 13.2.15 BIOLINQ INCORPORATED

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS